Claritev Corporation filings document a healthcare technology, data and insights issuer with Class A common stock listed on the NYSE under CTEV. Its Form 8-K reports furnish operating results, financial-condition updates, investor presentations and Regulation FD materials tied to its analytics, AI and claims-based healthcare cost-management platform.
Proxy and annual-meeting filings cover board elections, auditor ratification, executive compensation, stockholder votes and amendments to the Claritev Corporation 2020 Omnibus Incentive Plan. Other material-event reports address share-repurchase authorization, capital-structure matters and governance transitions.
Claritev Corporation, a healthcare technology and data company, reported Q2 2026 revenue of $257,478 thousand, up 6.6% year over year, driven by 13.7% growth in Claims Intelligence Solutions. Network Solutions and Payment & Revenue Integrity declined modestly. Operating income rose to $23,409 thousand, but interest expense of $100,253 thousand led to a net loss of $59,226 thousand (loss per share $3.49). EBITDA was $134,113 thousand and Adjusted EBITDA $155,799 thousand; Adjusted EPS was $1.41.
As of June 30, 2026, Claritev held $27.7 million in cash and restricted cash and carried gross long-term debt of $4,637,003 thousand, resulting in a total shareholders’ deficit of $287,839 thousand. The company had $70.0 million drawn and $273.6 million available under its $350.0 million revolving credit facility. Operating cash flow for the first half was $46,892 thousand, partly funding $84,847 thousand of capital expenditures tied to its Vision 2030 transformation program.
Claritev disclosed ongoing multidistrict antitrust litigation and a civil Department of Justice inquiry, while noting the DOJ closed a related antitrust grand jury proceeding and confirmed it was not pursuing a criminal investigation. One client represented 35.0% of Q2 revenue. Management reported a continuing material weakness in IT general controls, leaving disclosure controls not effective while remediation efforts continue.
Claritev Corporation reported second quarter 2026 results with revenues of $257.5 million, up 6.6% from $241.6 million in Q2 2025. Net loss was $59.2 million versus $62.6 million a year earlier, while Adjusted EBITDA rose 1.1% to $155.8 million, for a 60.5% margin compared with 63.8%.
The company generated strong cash metrics, with net cash from operating activities of $92.7 million versus $61.2 million and free cash flow of $54.6 million versus $36.6 million. Management highlighted more than $70 million in bookings in the first half of 2026 toward a $100 million full-year target.
Claritev raised its full-year 2026 outlook, guiding revenues to $1.00–$1.02 billion (from $985 million–$1.0 billion) and Adjusted EBITDA to $610–$620 million (from $605 million–$615 million), and increased free cash flow guidance to $5–$15 million. As of June 30, 2026, long-term debt was $4,588,160 (in thousands) and total shareholders’ deficit was $287,839 (in thousands).
Claritev Corporation filed a current report to disclose the death of board member John Prince. The company was notified of his passing on July 6, 2026. Prince had served on Claritev’s Board of Directors since June 2023 and was a member of the Audit Committee at the time of his death.
The filing notes that he was a respected director who will be greatly missed. Claritev does not describe any immediate changes to board or committee composition in this report, focusing instead on formally informing investors of his passing.
Albinson Brock reported acquisition or exercise transactions in this Form 4 filing.
Claritev Corp reported that SVP and Chief Accounting Officer Albinson Brock received a grant of 3,649 shares of Class A common stock in the form of restricted stock units. These RSUs vest in four equal 25% installments on June 30 of 2027, 2028, 2029 and 2030. Following this award, Brock directly holds 33,842 shares of Claritev common stock, reflecting a routine compensation-related equity grant rather than an open-market purchase.
Claritev Corporation reports that the U.S. Department of Justice Antitrust Division has closed an antitrust grand jury proceeding involving the company and informed Claritev it is not under any criminal investigation. The company welcomes this outcome and reiterates its belief that its solutions comply with antitrust laws.
Claritev also discloses that on May 19, 2026, it received a civil investigative demand from the DOJ Antitrust Division related to health insurance and is cooperating fully with information requests. The update is furnished under Regulation FD and is not incorporated into other securities law filings unless specifically referenced.
Claritev Corp senior vice president and chief people officer Carol Nutter made an open-market purchase of company stock. She bought 875 shares of Class A common stock at a price of $28.407 per share. After this transaction, she directly holds 46,941 shares of Claritev common stock.
Claritev Corp EVP and Chief Digital Officer Kim Michael reported an open-market purchase of 3,000 shares of Class A common stock at $16.65 per share. Following this transaction, Michael directly owns 185,878 shares, indicating a modest increase in personal equity exposure to Claritev.
Claritev Corp director Prince John Michael made an open‑market purchase of 10,000 shares of Class A common stock at $16.00 per share. Following this transaction, he now directly owns 31,662 shares of Claritev common stock.
Claritev Corp director, president, CEO and executive chair Dalton Travis reported open-market purchases of a total of 20,920 shares of Class A common stock on May 18, 2026. The transactions were made indirectly through his spouse’s Individual Retirement Account at weighted average prices in the low-$12 range.
Claritev Corporation furnished this report to address a media article about government scrutiny. The company explains that in August 2024 it received a confidential grand jury subpoena from the Antitrust Division of the Department of Justice in connection with an investigation regarding health insurance and has been cooperating fully. Claritev states that, over the subsequent two years, the DOJ has not informed the company that it is a target of the investigation. Management says it remains focused on working with healthcare clients and partners to improve transparency, access, and affordability, and includes standard cautionary language about forward-looking statements and legal risks.